Hi there,

If you think Democracy Now!’s reporting is a critical line of defense against war, climate catastrophe and authoritarianism, please make your donation of $10 or more right now. Today, a generous donor will DOUBLE your donation, which means it’ll go 2x as far to support our independent journalism. Democracy Now! is funded by you, and that’s why we’re counting on your donation to keep us going strong. Please give today. Every dollar makes a difference—in fact, gets doubled! Thank you so much.
-Amy Goodman

Hi there,

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.

Donate

Independent Global News

Donate

Independent Global News

Editions

English

Español

Follow

Democracy Now!

Hot Topics

COVAX to Begin Vaccine Delivery in Feb.; South Africa Paying 2.5x EU Prices for AstraZeneca Vaccine

HeadlineJan 25, 2021

In international news, the World Health Organization has struck a deal with Pfizer and BioNTech for up to 40 million vaccine doses for COVAX, the international effort to distribute the vaccine to poorer nations. COVAX is set to start distribution next month with a plan to deliver around 1.8 billion doses to 92 countries this year, which would cover just over one-quarter of their populations.

This comes as news that South Africa is paying nearly 2.5 times more for the Oxford-AstraZeneca vaccine than EU countries has prompted stronger calls to halt vaccine nationalism and price gouging. EU nations are reportedly paying less because they funded research and development of the vaccine.

Topics:

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.